Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VLA2001 COVID-19 Vaccine in Children (2-12 Years)
NCT05298644Phase 3Withdrawn
- Sponsor
- Valneva
- Start
- Oct 2022
- Primary completion
- Jul 2023
- Modality
- Viral Vector Vaccines, Whole Inactivated Vaccines
01
Overview
A Phase 3 trial of VLA2001 in coronavirus disease 2019 (COVID-19), sponsored by Valneva. Planned start Oct 2022; status: withdrawn.
02
Drugs
VLA2001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05298644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05298644.